Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

https://doi.org/10.1182/blood-2019-125155

Published: 2019

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2018-99-120103

Published: 2018

Journal Articles

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma

Stacey L. Fanning, PhD, Kira Goldgirsh, MS, Dante B. Descalzi-Montoya, PhD, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2018-99-118763

Published: 2018

Journal Articles

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Dante Descalzi-Montoya, PhD, Kira Goldgirsh, MS, Zheng Yang, MS, Eugenia Dziopa, MS, Iriana Colorado, MS, Rena Feinman, PhD, Themba Nyirenda, PhD, David H. Vesole, MD, Pashna N. Munshi, MD, Scott D. Rowley, MD, Noa Biran, MD, Joshua R Richter, MD, David Siegel, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2017) 130 (Supplement 1): 1862.

https://doi.org/10.1182/blood.V130.Suppl_1.1862.1862

Published: 2017

Journal Articles

Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

Robert Korngold, PhD, Kira Goldgirsh, MS, Themba Nyirenda, PhD, Phyllis McKiernan, APN, MSN, Ryan Emerson, PhD, Marissa Vignali, PhD, Julie Rubinstein, Harlan Robins, PhD, David Siegel, MD PhD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4506.

https://doi.org/10.1182/blood.V130.Suppl_1.4506.4506

Published: 2017

Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD

Blood (2017) 130 (Supplement 1): 1831.

https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831

Published: 2017

Journal Articles

Successful Renal Transplant Tolerance Following a Haplo-Identical Allogenic Hematopoietic Stem Cell Transplant - a Case Report and Review of Literature

Neil Shah, MD, Adam S. Vesole, BBA, Michele L. Donato, MD, David S. Siegel, MD PhD, Joshua R. Richter, MD, Noa Biran, MD, Alan P Skarbnik, MD, Robert Korngold, PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD

Blood (2016) 128 (22): 5879.

https://doi.org/10.1182/blood.V128.22.5879.5879

Published: 2016

Journal Articles

Inhibition of HIF Prolyl Hydroxylases Mitigate Gut Graft-Versus-Host Disease

Rena Feinman, PhD, Iriana Colorado, MSc, Keyi Wang, MSc, Eugenia Dziopa, MSc, Michael A Flynn, MSc, Kevin Peters, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2016) 128 (22): 3349.

https://doi.org/10.1182/blood.V128.22.3349.3349

Published: 2016

Journal Articles

Intestinal Epithelial HIF-2 Is Protective in Gut Graft-Versus-Host-Disease

Rena Feinman, PhD, Iriana Colorado, MSc, Keyi Wang, BSc, Eugenia Dziopa, MSc, Leah Dziopa, MSc, Zheng Yang, MSc, Robert Korngold, PhD

Blood (2015) 126 (23): 1865.

https://doi.org/10.1182/blood.V126.23.1865.1865

Published: 2015

Journal Articles

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Blood (2015) 126 (23): 65.

https://doi.org/10.1182/blood.V126.23.65.65

Published: 2015

Journal Articles

Intestinal Epithelial HIF-1 Plays a Protective Role in Gut Graft Versus Host Disease

Rena Feinman, PhD, Iriana Colorado, MSc, Jenny Zilberberg, PhD, Anita Sreedhar, BA, Eugenia Dziopa, Leah Dziopa, Zheng Yang, Robert Korngold, PhD

Blood (2014) 124 (21): 539.

https://doi.org/10.1182/blood.V124.21.539.539

Published: 2014

Journal Articles

The Hypoxia Inducible Factor-2/Arginase-1 Axis Plays An Adaptive Role In Gvhd

Rena Feinman, PhD, Iriana Colorado, MSc, Jenny Zilberberg, Ph.D., Thobekile T Ndlovu, Moshe Z Miller, BS, Leah Dziopa, Eugenia Dziopa, Robert Korngold, PhD

Blood (2013) 122 (21): 2006.

https://doi.org/10.1182/blood.V122.21.2006.2006

Published: 2013

Journal Articles

Inhibition Of The Immunoproteasome Subunit LMP7 Decreases Alloresponses In Both MHC-Mismatched and miHA-Disparate Murine Models Of Graft Versus Host Disease

Jennifer Matos, PhD, Zheng Yang, Eugenia Dziopa, Leah Dziopa, Christopher J. Kirk, Ph.D, Robert Korngold, PhD, Jenny Zilberberg, Ph.D.

Blood (2013) 122 (21): 4472.

https://doi.org/10.1182/blood.V122.21.4472.4472

Published: 2013

Journal Articles

A Role For MMP-3 In The Modulation Of Early T Cell Responses In Gvhd

Stephen M Rosenberg, Ph.D., Leah Dziopa, Jenny Zilberberg, Ph.D., Robert Korngold, PhD

Blood (2013) 122 (21): 3258.

https://doi.org/10.1182/blood.V122.21.3258.3258

Published: 2013

Journal Articles

Phase 2 clinical trial of rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Blood (2013) 121 (15): 2864–2874.

https://doi.org/10.1182/blood-2012-08-446872

Published: 2013

Includes: Supplemental data

Journal Articles

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Rachel B. Salit, MD, Frances T. Hakim, PhD, Michael R. Bishop, MD, Thea M. Friedman, PhD, Robert Korngold, PhD, Kira Goldgirsh, PhD, Sarfraz Memon, MD, Seth M. Steinberg, PhD, David Liewehr, MS, Daniel Peaceman, BS, Jennifer Wilder, RN, Kelly Bryant, RN, Daniel H. Fowler, MD, Juan Gea-Banacloche, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2012) 120 (21): 3054.

https://doi.org/10.1182/blood.V120.21.3054.3054

Published: 2012

NARROW

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Successful Renal Transplant Tolerance Following a Haplo-Identical Allogenic Hematopoietic Stem Cell Transplant - a Case Report and Review of Literature

Inhibition of HIF Prolyl Hydroxylases Mitigate Gut Graft-Versus-Host Disease

Intestinal Epithelial HIF-2 Is Protective in Gut Graft-Versus-Host-Disease

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Intestinal Epithelial HIF-1 Plays a Protective Role in Gut Graft Versus Host Disease

The Hypoxia Inducible Factor-2/Arginase-1 Axis Plays An Adaptive Role In Gvhd

Inhibition Of The Immunoproteasome Subunit LMP7 Decreases Alloresponses In Both MHC-Mismatched and miHA-Disparate Murine Models Of Graft Versus Host Disease

A Role For MMP-3 In The Modulation Of Early T Cell Responses In Gvhd

Phase 2 clinical trial of rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only